Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial ( NCT04707313 ) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.
- Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial ( NCT04707313 ) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.
- The study met its primary endpoint demonstrating statistically significant change in body weight from baseline.
- Placebo-adjusted reductions in mean body weight ranged from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks.
- In both populations, danuglipron demonstrated a safety and tolerability profile consistent with the mechanism of action.